Evolus (NASDAQ:EOLS) Issues Earnings Results, Misses Expectations By $0.02 EPS

Evolus (NASDAQ:EOLS) issued its earnings results on Monday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports. The company had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million.

Evolus Stock Performance

EOLS traded up $0.25 during midday trading on Monday, reaching $5.58. 2,093,911 shares of the company were exchanged, compared to its average volume of 1,174,458. The company’s fifty day moving average price is $4.68 and its 200 day moving average price is $5.63. The company has a market cap of $363.03 million, a price-to-earnings ratio of -6.89 and a beta of 1.28. Evolus has a one year low of $3.86 and a one year high of $12.24.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 13,669 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the completion of the sale, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. The trade was a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rui Avelar sold 29,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the sale, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This represents a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 163,504 shares of company stock valued at $797,184 over the last three months. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

Institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp bought a new position in shares of Evolus in the first quarter valued at approximately $158,000. Oxford Asset Management LLP bought a new position in shares of Evolus in the fourth quarter valued at approximately $152,000. Virtu Financial LLC bought a new position in shares of Evolus in the fourth quarter valued at approximately $151,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Evolus in the fourth quarter valued at approximately $144,000. Finally, Creative Planning bought a new position in shares of Evolus in the third quarter valued at approximately $138,000. 90.69% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th. HC Wainwright decreased their target price on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Stifel Nicolaus decreased their price objective on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Evolus currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.